Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting September 5 at 7 a.m. ET, featuring Calidi's proprietary RedTail platform technology designed to transform cancer treatment approaches.
The presentation's significance lies in showcasing Calidi's innovative approach to addressing one of oncology's most challenging problems: effectively treating metastatic cancer. The RedTail platform represents a potential breakthrough in systemic cancer therapy, featuring an engineered enveloped oncolytic virus specifically designed for targeted delivery to distant metastatic sites. This technology aims to overcome a critical limitation in current cancer treatments by protecting the therapeutic virus from immune system clearance while enabling precise targeting of cancer cells throughout the body.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal disease sites. The company's lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additional information about the company's developments can be found at https://ibn.fm/CLDI.
The implications of this presentation extend beyond investor interest to potential patient impact. If successful, Calidi's technology could provide new treatment options for patients with metastatic cancers who currently have limited therapeutic alternatives. The ability to systemically deliver genetic medicines directly to metastatic sites represents a significant advancement in precision oncology, potentially improving treatment outcomes and quality of life for cancer patients worldwide.
The investment community's attention to this presentation underscores the growing importance of innovative biotechnologies in addressing complex medical challenges. As cancer remains a leading cause of mortality globally, advancements in targeted therapy delivery systems like Calidi's RedTail platform could reshape treatment paradigms and create new standards of care in oncology. The full details of the presentation and additional company information are available through the official release at https://ibn.fm/85iH4.
